Loading...
XNAS
QDEL
Market cap2.09bUSD
Jun 10, Last price  
30.92USD
1D
2.35%
1Q
-16.14%
Jan 2017
44.35%
Name

QuidelOrtho Corp

Chart & Performance

D1W1MN
P/E
P/S
0.75
EPS
Div Yield, %
Shrs. gr., 5y
9.28%
Rev. gr., 5y
39.07%
Revenues
2.78b
-7.17%
92,299,000106,015,000118,065,000128,132,000164,282,000113,339,000158,603,000155,741,000175,410,000182,615,000196,129,000191,603,000277,743,000522,285,000534,890,0001,661,668,0001,698,551,0003,266,000,0002,997,800,0002,782,900,000
Net income
-2.03b
L+19,969.31%
-9,259,00021,718,00013,631,00018,848,00032,883,000-11,271,0007,633,0004,993,0007,390,000-7,074,000-6,079,000-13,808,000-8,165,00074,183,00072,921,000810,287,000704,200,000548,700,000-10,100,000-2,027,000,000
CFO
83m
-70.38%
1,222,00020,731,00027,342,00028,941,00072,843,000-10,293,00046,982,00019,633,00025,682,00035,686,00036,309,00011,815,00027,709,000136,345,000134,485,000629,763,000805,869,000885,300,000280,200,00083,000,000

Profile

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
IPO date
Feb 01, 1991
Employees
7,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122023‑002021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,782,900
-14.79%
2,997,800
 
3,266,000
 
Cost of revenue
1,715,100
2,513,400
2,141,500
Unusual Expense (Income)
NOPBT
1,067,800
484,400
1,124,500
NOPBT Margin
38.37%
16.16%
34.43%
Operating Taxes
(79,500)
(19,000)
187,200
Tax Rate
16.65%
NOPAT
1,147,300
503,400
937,300
Net income
(2,027,000)
-469.42%
(10,100)
 
548,700
 
Dividends
Dividend yield
Proceeds from repurchase of equity
5,000
4,400
(47,900)
BB yield
-0.17%
-0.09%
0.97%
Debt
Debt current
341,800
166,500
207,500
Long-term debt
334,400
2,646,700
2,803,600
Deferred revenue
400
9,400
Other long-term liabilities
2,196,600
84,000
74,400
Net debt
577,900
2,638,500
2,645,100
Cash flow
Cash from operating activities
83,000
280,200
885,300
CAPEX
(209,300)
(140,900)
Cash from investing activities
(149,900)
(187,600)
(1,644,200)
Cash from financing activities
48,800
(265,800)
252,000
FCF
1,080,000
Balance
Cash
98,300
167,300
345,000
Long term investments
7,400
21,000
Excess cash
24,810
202,700
Stockholders' equity
99,700
2,157,900
2,130,300
Invested Capital
5,690,100
7,678,790
7,588,800
ROIC
17.28%
6.56%
12.35%
ROCE
18.52%
6.13%
14.05%
EV
Common stock shares outstanding
67,200
66,800
57,400
Price
44.25
-48.35%
73.70
 
85.67
 
Market cap
2,973,600
-39.53%
4,923,160
 
4,917,458
 
EV
3,551,500
7,561,660
7,562,558
EBITDA
1,067,800
941,600
1,408,100
EV/EBITDA
3.33
8.03
5.37
Interest
188,300
178,900
75,700
Interest/NOPBT
17.63%
36.93%
6.73%